Oscar Lahoud

Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder et al. · Journal of Clinical Oncology · 2021 · 199 citations · Full text

Medicine, Oncology, Pharmacology +13

Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Ola Landgren, Malin Hultcrantz, Benjamin Diamond et al. · JAMA Oncology · 2021 · 120 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial

Sham Mailankody, Arnab Ghosh, Terence J. Purdon et al. · Blood · 2018 · 100 citations

Medicine, Oncology, Pharmacokinetics +17

Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial

Benjamin Diamond, Neha Korde, Alexander M. Lesokhin et al. · The Lancet Haematology · 2021 · 95 citations

Medicine, Hematology, Oncology +15

Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Lindsey E. Roeker, Peter Dreger, Jennifer R. Brown et al. · Blood Advances · 2020 · 86 citations · Full text

Medicine, Immunology, Oncology +17